Patents for A61P 35 - Antineoplastic agents (221,099)
05/2004
05/25/2004US6740656 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
05/25/2004US6740655 3',5'-cyclic nucleotide phosphodiesterase 4-specific inhibitors reduce eosinophil influx to the lungs; side effect reduction; antiinflammatory agent; antiallergens; respiratory system disorders, especially asthma
05/25/2004US6740651 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
05/25/2004US6740645 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
05/25/2004US6740640 Polymerase inhibitor; anticancer agent
05/25/2004US6740512 Eukaryotic neutral sphingomyelinase (nsmase); used in drugs and in diagnosis
05/25/2004US6740511 Comprising mutations at one or more residues within the region of fiber stretching; used in gene therapy
05/25/2004US6740320 Recombinant P53 adenovirus methods and compositions
05/25/2004US6740304 Receptor binding conjugates
05/21/2004WO2004042402A2 Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
05/21/2004WO2004042342A2 Nuclear pore protein nup88 as a novel target
05/21/2004WO2004041867A2 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
05/21/2004WO2004041865A2 Stabilized single domain antibodies
05/21/2004WO2004041863A2 Single domain antibodies directed against interferon- gamma and uses therefor
05/21/2004WO2004041862A2 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
05/21/2004WO2004041859A2 Peptide fragments of the harp factor inhibiting angiogenesis
05/21/2004WO2004041837A1 Novel cytarabine monophosphate prodrugs
05/21/2004WO2004041834A2 Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
05/21/2004WO2004041829A1 Quinazoline derivatives as src tyrosine kinase inhibitors
05/21/2004WO2004041828A1 Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
05/21/2004WO2004041822A1 Pyrimido[4,5-d]pyrimidine derivatives with anticancer activity
05/21/2004WO2004041821A1 Pyrimido compounds having antiproliferative activity (ii)
05/21/2004WO2004041817A1 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof
05/21/2004WO2004041812A1 Therapeutic compounds and methods
05/21/2004WO2004041811A1 3-cyano-quinoline derivatives
05/21/2004WO2004041794A1 Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
05/21/2004WO2004041308A1 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
05/21/2004WO2004041307A2 Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
05/21/2004WO2004041297A2 Modified cytokines for use in cancer therapy
05/21/2004WO2004041268A1 Combination comprising docetaxel and a cdk inhibitor
05/21/2004WO2004041267A1 Combination comprising a cdk inhibitor and cisplatin
05/21/2004WO2004041266A1 Receptor function controlling agent
05/21/2004WO2004041262A1 Combination of a cdk inhibitor and mitoxantrone
05/21/2004WO2004018473A3 Azapurine derivatives
05/21/2004WO2004014222A3 Diagnosis and treatment of tuberous sclerosis
05/21/2004WO2004005476A3 Nucleic acid compositions for stimulating immune responses
05/21/2004WO2004000817A3 Benzimidazole compounds and their use as estrogen agonists/antagonists
05/21/2004WO2003104426A3 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
05/21/2004WO2003103569A3 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
05/21/2004WO2003101455A3 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
05/21/2004WO2003089462A3 Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
05/21/2004WO2003088900A3 Solid forms of salts with tyrosine kinase activity
05/21/2004WO2003085110A3 Oligomeric compounds for the modulation hif-1alpha expression
05/21/2004WO2003084935A3 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
05/21/2004WO2003080638A3 Antisense iap nucleobase oligomers and uses thereof
05/21/2004WO2003080105A3 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
05/21/2004WO2003072725A3 Recombinant negative strand virus rna expression systems and vaccines
05/21/2004WO2003040296A8 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
05/21/2004WO2003013422A3 Methods for the treatment and prognosis of leukemia and other cancer types
05/21/2004WO2003005493A8 Apparatus for a quick release safety connector assembly
05/21/2004WO2002102307B1 Nucleoside vaccine adjuvants
05/21/2004WO2002102306A8 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
05/21/2004WO2002090361A8 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
05/21/2004WO2002067862A3 Regulation of the ctl response by macrophage migration inhibitory factor
05/21/2004WO2002061105A8 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
05/21/2004WO2000058340A3 50 human secreted proteins
05/21/2004CA2505326A1 Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
05/21/2004CA2505325A1 Stabilized single domain antibodies
05/21/2004CA2505322A1 Receptor function regulator
05/21/2004CA2505316A1 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
05/21/2004CA2504999A1 Therapeutic compounds and methods
05/21/2004CA2504270A1 Peptide fragments of the harp factor inhibiting angiogenesis
05/21/2004CA2503115A1 Combination of a cdk inhibitor and mitoxantrone
05/21/2004CA2502979A1 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
05/21/2004CA2502973A1 Combination comprising docetaxel and a cdk inhibitor
05/21/2004CA2502969A1 Combination comprising a cdk inhibitor and cisplatin
05/21/2004CA2502182A1 Pyrimido[4,5-d]pyrimidine derivatives with anticancer activity
05/21/2004CA2502180A1 Pyrimido compounds having antiproliferative activity (ii)
05/20/2004US20040097739 Ppar delta activators
05/20/2004US20040097735 Mercaptan containing diagnostic agents for imaging malignant melanoma and distant metastases and rhenium (186Re, 188Re) therapeutic complexes for treating the same
05/20/2004US20040097734 Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses
05/20/2004US20040097733 Bicyclic aromatic or heteroaromatic-amine compounds; Regulators of cell proliferation and differentiation; useful for treating skin related diseases; retinoid antagonist or retinoid inverse agonist-like biological activity
05/20/2004US20040097714 Using microfiltration and/or diafiltration to isolate transforming growth factor from dairy products for use in treatment and prevention of cell proliferative, autoimmune, bone and inflammatory disorders; antitumor agents
05/20/2004US20040097703 Cancer antigen peptide for treatment cell proliferative and cancer disorders
05/20/2004US20040097589 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
05/20/2004US20040097580 For therapy and prophylaxis of diseases or disorders induced by promotion of lipid peroxidation or accumulation of oxidized products
05/20/2004US20040097579 Taxane formulations
05/20/2004US20040097576 Use of tryptophane-derivatives, that are toxicated into specific toxins in body's cell by enzymes tryptophan-hydroxylase and aromatic amino acid decarboxylase of body, for simultaneous reduction and/or disruption of serotonin
05/20/2004US20040097571 Imidazole compounds and their use as adenosine deaminase inhibitors
05/20/2004US20040097563 4-6-Diphenyl pyridine derivatives as antiinflammatory agents
05/20/2004US20040097551 As inhibitors of glucosylceramide synthase; for therapy and prophylaxis
05/20/2004US20040097550 For therapy of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, tumours, tumour diseases and/or tumour metastases
05/20/2004US20040097545 Quinolinone derivatives
05/20/2004US20040097539 Hsp inductor
05/20/2004US20040097530 Novel heteroaryl derivatives and their use as medicaments
05/20/2004US20040097521 Clinical treatment
05/20/2004US20040097519 Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber- 5-yl)piperazin-1-yl]- 2-hydroxypropoxy}quinoline
05/20/2004US20040097517 Novel imidazopyridines as cyclin dependent kinase inhibitors
05/20/2004US20040097516 For therapy of cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases
05/20/2004US20040097507 Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1
05/20/2004US20040097506 Pyrimidine derivatives for inhibition of cell proliferation
05/20/2004US20040097502 For therapy and prophylaxis of disorders characterised by overexpression of transforming growth factor
05/20/2004US20040097501 Triazole compounds useful as protein kinase inhibitors
05/20/2004US20040097497 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
05/20/2004US20040097495 Method for treating fibrotic diseases or other indications IIIC
05/20/2004US20040097494 For use as nitric oxide synthase inhibitors
05/20/2004US20040097493 Diazinopyrimidines
05/20/2004US20040097487 To inhibits matrix metalloprotease activity
05/20/2004US20040097470 Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
05/20/2004US20040097463 Administering to a subject in need of such treatment an amount of a formulation comprising an isolated molecule selected from the group consisting of asiatic acid and asiaticoside